SLC2A1 and cancer: MRX34, a miR-34a mimic that is effective to suppress tumor progression in animal models through multiple mechanisms including the interference with cancer metabolism via regulating SLC2A1 expression (He et al., 2019; Hong M. et al., 2020), was the first anticancer miRNA to reach phase I clinical trials, but the trial ended in 2016 due to the occurrence of severe immune-related adverse events and even mortality (Hong D. S. et al., 2020).